Design, Synthesis, and Testing of Breast Cancer Angiogenesis Inhibitors
Abstract
Tumor angiogenesis is the process by which a growing tumor mass recruits the new blood vessels required for its continued growth, and through which the tumor can spread to distant sites. Indeed the neovascularization process is thought to be one of the rate limiting steps for the growth of primary and metastatic breast tumors. This proposal will focus on the development of inhibitors of a particular angiogenic factor, thymidine phosphorylase/platelet-derived endothelial cell growth factor (TP/PD-ECGF). These inhibitors will target the enzymatic activity of TP/PD-ECGF, since it has been found to be required for angiogenesis. In the past year, several compounds were synthesized as potential TP inhibitors, including one having high potency as an enzyme inhibitor in vitro (IC50 = 1.5 muM). This compound will now be tested in biological assays.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1998
- Accession Number
- ADB240398
Entities
People
- Edward L. Schwartz